L&K Bio accelerates US spinal implant business via NASS 2026

L&K Bio’s US subsidiary, L&K Spine, has established a business execution schedule for its spinal implant products following participation in the North American Spine Society (NASS 2026) meeting in Texas.

The company promoted its BluEX-C cervical expandable cage, which received FDA approval in May. L&K Spine reported reaching 50 cumulative cervical surgery levels in the US market and is working to expand hospital registrations and clinical applications.

In collaboration with spinal surgery expert Dr. K. Daniel Riew, the company is pursuing the ‘New Cervical Project’ to expand its cervical implant lineup. Additionally, L&K Bio is discussing supply chain expansion in the European market following meetings at the EUROSPINE conference.